BOSTON — A drug company has agreed to pay $185,000 and stop marketing its opioids through in-person detailing of Massachusetts prescribers and speaker programs with healthcare professionals, resolving allegations of unfair and deceptive practices, according to the state Attorney General’s Office.

The assurance of discontinuance, filed in Suffolk Superior Court, is the result of an investigation by the AG’s Office of Collegium Pharmaceutical, Inc.’s deceptive marketing of its opioid product, Xtampza ER. According to the AG’s Office, Collegium sales representatives misled doctors about the potential risks of the drug by marketing it as a safe and responsible alternative to other opioids, even though Xtampza has the same active ingredient (oxycodone) as other drugs like Oxycontin.

Prior to 2018, Collegium also marketed its drug through sponsored “speaker programs” at which a physician or other health care professional made a speech or presentation to other health care professionals about the drug. Under the AG’s agreement, Collegium will permanently end speaker programs and in-person detailing tactics to promote Xtampza in Massachusetts.